公开(公告)号：US20100022542A1

公开(公告)日：2010-01-28

申请号：US12504604

申请日：2009-07-16

申请人： Hiroshi TAKEMOTO ,  Takeshi SHIOTA ,  Masami TAKAYAMA

发明人： Hiroshi TAKEMOTO ,  Takeshi SHIOTA ,  Masami TAKAYAMA

IPC分类号： A61K31/5377 ,  C07D277/00 ,  A61K31/425 ,  C07D417/02 ,  A61K31/4439 ,  A61P7/02

CPC分类号： C07D285/16 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  C07D231/40 ,  C07D249/14 ,  C07D277/46 ,  C07D277/82 ,  C07D285/18 ,  C07D333/38 ,  C07D417/04 ,  C07D417/14

摘要： Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X1—Y1-Z1-W1  (I) wherein X1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y1 is —NRACO—(CH2)0-2— or the like (wherein RA is a hydrogen or the like); Z1 is optionally substituted phenylene or the like; and W1 is a group represented by the below formula: wherein R1, R2, R3, and R4 are each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line (---) represents the presence or absence of bond.

摘要翻译： 含有通式（I）的化合物，其前药，二者的药学上可接受的盐或它们的溶剂化物并显示血小板生成素受体激动作用的药物组合物：X1-Y1-Z1-W1（Ⅰ）其中X1是 任选取代的芳基，任选取代的杂芳基等; Y1是-NRACO-（CH 2）0-2-等（其中RA是氢等）; Z1是任选取代的亚苯基等; 并且W1是由下式表示的基团：其中R1，R2，R3和R4各自独立地为氢原子，任选取代的低级烷基等，虚线（---）表示存在或不存在键 。